Martin Falbisoner / Wikimedia Commons
Why It Matters
The Senate Health, Education, Labor and Pensions Committee has advanced Dr. Erica Schwartz’s nomination to lead the Centers for Disease Control and Prevention, moving her toward a full chamber vote. The CDC director role is among the most visible health positions in the federal government, shaping disease surveillance, emergency response, and public health guidance that affects Americans nationwide. Committee approval signals the nomination is on track, though confirmation likely remains weeks away.
What Happened
The Senate committee voted Thursday on Schwartz’s nomination and that of Sean Kaufman, tapped to lead the Administration for Strategic Preparedness and Response. All Republican committee members supported Schwartz’s advancement, and she gained support from at least one Democrat—Sen. Tim Kaine of Virginia—allowing her to move forward.
Committee members voted along strict party lines on Kaufman’s nomination, with Republicans backing his advancement and Democrats opposing it.
Sen. Bill Cassidy, the committee’s Republican chairman, announced his support for both nominees Thursday morning. Cassidy acknowledged ongoing questions about vaccine-related claims, noting that “any assertion that there is a link between autism and vaccines is wrong.” He also expressed concern about Kaufman’s past statements on immunization, saying Kaufman “has said some pretty stupid things, and really harmful things, regarding immunization.”
Timeline to Confirmation
A full Senate vote on Schwartz’s nomination is unlikely before the chamber begins its August recess. Both nominees are expected to remain in committee limbo through August and into early September before facing votes on the Senate floor.
The timing reflects the typical pace of health-related confirmations and the Senate’s August break, which will slow momentum for any floor action in the coming weeks.
Context: Recent CDC Website Changes
The nomination advance comes as the Department of Health and Human Services made edits last week to CDC website language addressing vaccines and autism—a topic that has drawn scrutiny from lawmakers. Cassidy’s comments suggest the committee is aware of these changes and the broader discussion surrounding vaccine safety claims.
The CDC has long maintained that vaccines do not cause autism, a position supported by decades of scientific research. Any changes to how the agency communicates that message have drawn attention from committee members concerned about maintaining clear public health guidance.
Schwartz’s Path Forward
Schwartz’s bipartisan support in committee—including backing from Kaine—may ease her path to confirmation when the full Senate votes. Committee approval with Democratic support typically signals a nominee faces lower resistance on the chamber floor, though votes can shift as senators weigh competing priorities.
Kaufman’s strictly party-line committee vote suggests his confirmation battle may be more contentious, with Democrats unified in opposition. His past statements on vaccines and immunization appear to be a focal point for Democratic criticism, as evidenced by Cassidy’s own acknowledgment of the concerns.
What’s Next
Both nominees will remain in the queue for Senate floor votes after the August recess concludes in September. Schwartz is likely to move first, given her committee-wide support. Leadership will determine the schedule and priority for floor votes in the fall legislative calendar.
The confirmations are part of the Trump administration’s effort to reshape leadership at federal health agencies, reflecting its approach to public health policy and pandemic-related messaging.
About the Author
